DC
TPST icon

Davenport & Co’s Tempest Therapeutics TPST Stock Holding History

Davenport & Co’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,846
Closed -$36.9K – 1248
2025
Q1 		$36.9K Hold
3,846
– – ﹤0.01% 1165
2024
Q4 		$41.7K Hold
3,846
– – ﹤0.01% 1145
2024
Q3 		$70K Hold
3,846
– – ﹤0.01% 1131
2024
Q2 		$110K Buy
+3,846
New +$166K ﹤0.01% 1098

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Davenport & Co's TPST Position: Q2 2025 in Review

Davenport & Co sold out of Tempest Therapeutics (TPST) in Q2 2025, closing a stake of 3,846 shares — an estimated $36.9K sold.

Davenport & Co first reported a position in TPST in Q2 2024 and held it in 4 quarters. The position peaked at $110K in Q2 2024. 18 funds tracked by Wall St. Rank hold TPST as of Q2 2025.

  • Davenport & Co reported no remaining Tempest Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Davenport & Co sold 3,846 Tempest Therapeutics shares in Q2 2025, an estimated $36.9K.
  • Davenport & Co first reported a position in Tempest Therapeutics in Q2 2024 and held it in 4 quarters.
  • Davenport & Co's Tempest Therapeutics position peaked at $110K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2025.

Based on Davenport & Co's 13F filing for Q2 2025, filed 22 Jul 2025.